<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4554">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 18, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04755972</url>
  </required_header>
  <id_info>
    <org_study_id>2181-147-01/06/M.S.-20-02</org_study_id>
    <nct_id>NCT04755972</nct_id>
  </id_info>
  <brief_title>Mucolytics in Patients on Invasive Mechanical Ventilation Due to Severe Acute Respiratory Syndrome Coronavirus 2</brief_title>
  <official_title>Mucolytic Agents and Ventilator-associated Pneumonia in Patients on Invasive Mechanical Ventilation Due to Severe Acute Respiratory Syndrome Coronavirus 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Hospital Center, Split</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinical Hospital Center, Split</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is planned to include patients over 18 years of age of both sexes, admitted to the&#xD;
      Intensive Care Unit of Clinical Hospital Centre Split for respiratory insufficiency caused by&#xD;
      severe acute respiratory syndrome coronavirus 2 in need of invasive mechanical ventilation.&#xD;
&#xD;
      The patients will be divided into four groups. Group 1 will receive N-acetylcysteine&#xD;
      inhalation, Group 2 will receive inhalation with a 5% sodium chloride solution, and Group 3&#xD;
      will receive inhalation of 8.4% sodium bicarbonate, group 4 is a control group and will not&#xD;
      routinely receive inhaled mucolytics preventively.&#xD;
&#xD;
      All inhalations will be given twice a day 12 hours apart. The first inhalation will be&#xD;
      included within 12 hours of the patient being enrolled in the Intensive Care Unit. Patients&#xD;
      will be randomized according to the type of inhalation they will receive, randomization will&#xD;
      be done by all researchers through the random.org website, and the inhalation will be given&#xD;
      by a nurse according to the agreed protocol.&#xD;
&#xD;
      RESEARCH GOALS&#xD;
&#xD;
      The aim of this study is to determine whether there is a difference in the frequency and&#xD;
      duration of ventilator-associated pneumonia (VAP) and whether there is a difference in the&#xD;
      number of days spent on mechanical ventilation and in mortality in these four groups of&#xD;
      patients.&#xD;
&#xD;
      Hypothesis&#xD;
&#xD;
      Coronavirus disease 2019 patients on invasive mechanical ventilation and preventive sodium&#xD;
      bicarbonate inhalation will have a lower incidence of ventilator-associated pneumonia and&#xD;
      fewer days spent on invasive mechanical ventilation than patients inhaled with&#xD;
      N-acetylcysteine, 5% saline, or patients without preventive inhalation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2021</start_date>
  <completion_date type="Anticipated">August 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 29, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference between 4 arms regarding ventilator-associated pneumonia rate</measure>
    <time_frame>Through study completion, an average of 6 months.</time_frame>
    <description>Patients will be monitored for ventilator-associated pneumonia according to clinical criteria with a new or progressive pulmonary infiltrate on imaging plus supportive clinical findings of infection (eg, fever, secretions, leukocytosis). The diagnosis is confirmed when lower respiratory tract sampling identifies a pathogen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of ventilator-free days</measure>
    <time_frame>Day 28 after ICU admission.</time_frame>
    <description>Number of days from day 1 after ICU admission and start of mechanical ventilation on which a patient breathes without assistance of the ventilator if the period of unassisted breathing lasted at least 24 consecutive hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 28 after ICU admission.</time_frame>
    <description>Life status (alive or deceased) on day 28 after ICU admission.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Corona Virus Infection</condition>
  <condition>Pneumonia, Ventilator-Associated</condition>
  <arm_group>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inhalation of 5 ml-s of N-acetylcysteine every 12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertonic saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inhalation of 5 ml-s of 5% sodium chloride every 12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bicarbonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inhalation of 5 ml-s 8.4% sodium bicarbonate every 12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No preventive inhalation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Inhalation of N-acetylcysteine</intervention_name>
    <description>Group 1 will receive N-acetylcysteine inhalation every 12 hours from the beginning of invasive mechanical ventilation.</description>
    <arm_group_label>N-acetylcysteine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Inhalation of 5% sodium chloride</intervention_name>
    <description>Group 2 will receive inhalation with a 5% sodium chloride solution every 12 hours from the beginning of invasive mechanical ventilation.</description>
    <arm_group_label>Hypertonic saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Inhalation of 8,4% sodium bicarbonate</intervention_name>
    <description>Group 3 will receive inhalation of 8.4% sodium bicarbonate every 12 hours from the beginning of invasive mechanical ventilation.</description>
    <arm_group_label>Bicarbonate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 18 years of age with coronavirus pneumonia who need invasive mechanical&#xD;
             ventilation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with polytrauma,&#xD;
&#xD;
          -  pregnant women,&#xD;
&#xD;
          -  severe hemodynamic instability,&#xD;
&#xD;
          -  patients with pulmonary edema,&#xD;
&#xD;
          -  less than 3 days spent in the ICU,&#xD;
&#xD;
          -  patients who have microbiologically proven bacterial infection on arrival.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nikola Delić, MD</last_name>
    <phone>+385989000150</phone>
    <email>nkldelic@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Hospital Centre Split</name>
      <address>
        <city>Split</city>
        <zip>21000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikola Delić, MD</last_name>
      <phone>+385989000150</phone>
      <email>nkldelic@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 6, 2021</study_first_submitted>
  <study_first_submitted_qc>February 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>February 13, 2021</last_update_submitted>
  <last_update_submitted_qc>February 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinical Hospital Center, Split</investigator_affiliation>
    <investigator_full_name>Nikola Delić</investigator_full_name>
    <investigator_title>MD, intensive care specialist</investigator_title>
  </responsible_party>
  <keyword>coronavirus disease 2019</keyword>
  <keyword>Pneumonia, Ventilator-Associated</keyword>
  <keyword>hypertonic saline</keyword>
  <keyword>bicarbonate</keyword>
  <keyword>N-acetylcysteine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

